NeoPhore

Neobe

The company develops engineered microbial biotherapeutics designed to disrupt the microenvironment of solid tumours for cancer patients receiving immunotherapy.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.

Neogene Therapeutics

This biotechnology company develops engineered T cell receptor therapies targeting neoantigens in solid cancers for patients with oncology needs.

Enara Bio

This company develops cancer immunotherapies targeting antigens derived from the dark genome for patients with solid tumours.

NKIO

This company develops natural killer cell therapies and small molecule medicines to treat solid tumours for patients with cancer and inflammatory diseases.

iOnctura

The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.

Cytospire Therapeutics

This company develops multispecific immune cell engager antibodies for cancer patients to enhance and direct immune system activity against solid tumours.

Theolytics

The company develops oncolytic viral immunotherapies for patients with solid tumours.